Your browser doesn't support javascript.
loading
Integrative Analysis Reveals a Molecular Stratification of Systemic Autoimmune Diseases.
Barturen, Guillermo; Babaei, Sepideh; Català-Moll, Francesc; Martínez-Bueno, Manuel; Makowska, Zuzanna; Martorell-Marugán, Jordi; Carmona-Sáez, Pedro; Toro-Domínguez, Daniel; Carnero-Montoro, Elena; Teruel, María; Kerick, Martin; Acosta-Herrera, Marialbert; Le Lann, Lucas; Jamin, Christophe; Rodríguez-Ubreva, Javier; García-Gómez, Antonio; Kageyama, Jorge; Buttgereit, Anne; Hayat, Sikander; Mueller, Joerg; Lesche, Ralf; Hernandez-Fuentes, Maria; Juarez, Maria; Rowley, Tania; White, Ian; Marañón, Concepción; Gomes Anjos, Tania; Varela, Nieves; Aguilar-Quesada, Rocío; Garrancho, Francisco Javier; López-Berrio, Antonio; Rodriguez Maresca, Manuel; Navarro-Linares, Héctor; Almeida, Isabel; Azevedo, Nancy; Brandão, Mariana; Campar, Ana; Faria, Raquel; Farinha, Fátima; Marinho, António; Neves, Esmeralda; Tavares, Ana; Vasconcelos, Carlos; Trombetta, Elena; Montanelli, Gaia; Vigone, Barbara; Alvarez-Errico, Damiana; Li, Tianlu; Thiagaran, Divya; Blanco Alonso, Ricardo.
Afiliación
  • Barturen G; Pfizer-University of Granada-Junta de Andalucía Centre for Genomics and Oncological Research, Granada, Spain.
  • Babaei S; Bayer, Berlin, Germany.
  • Català-Moll F; Bellvitge Biomedical Research Institute, Barcelona, Spain.
  • Martínez-Bueno M; Pfizer-University of Granada-Junta de Andalucía Centre for Genomics and Oncological Research, Granada, Spain.
  • Makowska Z; Bayer, Berlin, Germany.
  • Martorell-Marugán J; Pfizer-University of Granada-Junta de Andalucía Centre for Genomics and Oncological Research, Granada, Spain.
  • Carmona-Sáez P; Pfizer-University of Granada-Junta de Andalucía Centre for Genomics and Oncological Research, Granada, Spain.
  • Toro-Domínguez D; Pfizer-University of Granada-Junta de Andalucía Centre for Genomics and Oncological Research, Granada, Spain.
  • Carnero-Montoro E; Pfizer-University of Granada-Junta de Andalucía Centre for Genomics and Oncological Research, Granada, Spain.
  • Teruel M; Pfizer-University of Granada-Junta de Andalucía Centre for Genomics and Oncological Research, Granada, Spain.
  • Kerick M; Institute of Parasitology and Biomedicine "López Neyra", Spanish National Research Council, Granada, Spain.
  • Acosta-Herrera M; Institute of Parasitology and Biomedicine "López Neyra", Spanish National Research Council, Granada, Spain.
  • Le Lann L; Université de Brest, Centre Hospitalier Universitaire de Brest, INSERM, and Labex IGO, Brest, France.
  • Jamin C; Université de Brest, Centre Hospitalier Universitaire de Brest, INSERM, and Labex IGO, Brest, France.
  • Rodríguez-Ubreva J; Bellvitge Biomedical Research Institute, Barcelona, Spain.
  • García-Gómez A; Bellvitge Biomedical Research Institute, Barcelona, Spain.
  • Kageyama J; Bayer, Berlin, Germany.
  • Buttgereit A; Bayer, Berlin, Germany.
  • Hayat S; Bayer, Berlin, Germany.
  • Mueller J; Bayer, Berlin, Germany.
  • Lesche R; Bayer, Berlin, Germany.
  • Hernandez-Fuentes M; UCB, Slough, UK.
  • Juarez M; UCB, Slough, UK.
  • Rowley T; UCB, Slough, UK.
  • White I; UCB, Slough, UK.
  • Marañón C; Pfizer-University of Granada-Junta de Andalucía Centre for Genomics and Oncological Research, Granada, Spain.
  • Gomes Anjos T; Pfizer-University of Granada-Junta de Andalucía Centre for Genomics and Oncological Research, Granada, Spain.
  • Varela N; Pfizer-University of Granada-Junta de Andalucía Centre for Genomics and Oncological Research, Granada, Spain.
  • Aguilar-Quesada R; Andalusian Public Health System Biobank, Granada, Spain.
  • Garrancho FJ; Andalusian Public Health System Biobank, Granada, Spain.
  • López-Berrio A; Andalusian Public Health System Biobank, Granada, Spain.
  • Rodriguez Maresca M; Andalusian Public Health System Biobank, Granada, Spain.
  • Navarro-Linares H; Andalusian Public Health System Biobank, Granada, Spain.
  • Almeida I; Centro Hospitalar do Porto, Porto, Portugal.
  • Azevedo N; Centro Hospitalar do Porto, Porto, Portugal.
  • Brandão M; Centro Hospitalar do Porto, Porto, Portugal.
  • Campar A; Centro Hospitalar do Porto, Porto, Portugal.
  • Faria R; Centro Hospitalar do Porto, Porto, Portugal.
  • Farinha F; Centro Hospitalar do Porto, Porto, Portugal.
  • Marinho A; Centro Hospitalar do Porto, Porto, Portugal.
  • Neves E; Centro Hospitalar do Porto, Porto, Portugal.
  • Tavares A; Centro Hospitalar do Porto, Porto, Portugal.
  • Vasconcelos C; Centro Hospitalar do Porto, Porto, Portugal.
  • Trombetta E; Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
  • Montanelli G; Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
  • Vigone B; Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
  • Alvarez-Errico D; Bellvitge Biomedical Research Institute, Barcelona, Spain.
  • Li T; Bellvitge Biomedical Research Institute, Barcelona, Spain.
  • Thiagaran D; Karolinska Institutet, Stockholm, Sweden.
  • Blanco Alonso R; Hospital Universitario Marqués de Valdecilla, IDIVAL, Universidad de Cantabria, Santander, Spain.
Arthritis Rheumatol ; 73(6): 1073-1085, 2021 06.
Article en En | MEDLINE | ID: mdl-33497037
ABSTRACT

OBJECTIVE:

Clinical heterogeneity, a hallmark of systemic autoimmune diseases, impedes early diagnosis and effective treatment, issues that may be addressed if patients could be classified into groups defined by molecular pattern. This study was undertaken to identify molecular clusters for reclassifying systemic autoimmune diseases independently of clinical diagnosis.

METHODS:

Unsupervised clustering of integrated whole blood transcriptome and methylome cross-sectional data on 955 patients with 7 systemic autoimmune diseases and 267 healthy controls was undertaken. In addition, an inception cohort was prospectively followed up for 6 or 14 months to validate the results and analyze whether or not cluster assignment changed over time.

RESULTS:

Four clusters were identified and validated. Three were pathologic, representing "inflammatory," "lymphoid," and "interferon" patterns. Each included all diagnoses and was defined by genetic, clinical, serologic, and cellular features. A fourth cluster with no specific molecular pattern was associated with low disease activity and included healthy controls. A longitudinal and independent inception cohort showed a relapse-remission pattern, where patients remained in their pathologic cluster, moving only to the healthy one, thus showing that the molecular clusters remained stable over time and that single pathogenic molecular signatures characterized each individual patient.

CONCLUSION:

Patients with systemic autoimmune diseases can be jointly stratified into 3 stable disease clusters with specific molecular patterns differentiating different molecular disease mechanisms. These results have important implications for future clinical trials and the study of nonresponse to therapy, marking a paradigm shift in our view of systemic autoimmune diseases.
Asunto(s)

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Enfermedades Autoinmunes / Perfilación de la Expresión Génica / Epigenoma Tipo de estudio: Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies / Screening_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Arthritis Rheumatol Año: 2021 Tipo del documento: Article País de afiliación: España

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Enfermedades Autoinmunes / Perfilación de la Expresión Génica / Epigenoma Tipo de estudio: Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies / Screening_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Arthritis Rheumatol Año: 2021 Tipo del documento: Article País de afiliación: España